Obstructive Sleep Apnea SURMOUNT-OSA trials investigated GLP2 in adults with moderate-to-severe obstructive sleep apnea and obesity: Significant improvements in apnea-hypopnea index (AHI) from baseline Benefits observed in participants both using and not using positive airway pressure therapy Improvements correlated with weight reduction FDA approval granted in December 2024 for moderate-to-severe OSA treatment Diabetes Prevention Extended follow-up from SURMOUNT-1 assessed diabetes prevention in participants with prediabetes: 94% reduction in progression to type 2 diabetes compared to placebo over 3 years Nearly all participants with prediabetes at baseline converted to normoglycemia Effects diminished during off-treatment follow-up period, indicating ongoing treatment benefit [CALLOUT BOX Highlighted] Important Context: While GLP2 has demonstrated substantial efficacy in multiple large-scale clinical trials, the majority of data comes from industry-sponsored studies with relatively short follow-up periods (40-72 weeks for most trials)
When these signals are better balanced, many people find it easier to eat smaller portions, avoid constant snacking, and stay satisfied longer between meals
Clarifying the mechanisms underlying these effects requires deeper exploration of tirzepatides distinct physiological actions beyond glucose control
GLP-1 medications, such as Ozempic, Trulicity, and Wegovy, are designed to replicate these natural actions of GLP-1
These therapies work through metabolic and appetite-regulation pathways that may help support glucose balance and weight management under the supervision of a licensed healthcare provider
Semaglutide intermediates: CAS No
